ERBB2 and breast cancer: In the MonarchE study, adjuvant abemaciclib demonstrated sustained benefit in reducing the risk of recurrence and distant metastasis in hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer [24].